Association of carbamylated high-density lipoprotein with coronary artery disease in type 2 diabetes mellitus: carbamylated high-density lipoprotein of patients promotes monocyte adhesion

Increasing evidence showed that carbamylated lipoprotein accelerated atherosclerosis. However, whether such modification of high-density lipoprotein (HDL) particles alters in type 2 diabetes mellitus (T2DM) patients and facilitates vascular complications remains unclear. We aimed to investigate the...

Full description

Saved in:
Bibliographic Details
Published inJournal of translational medicine Vol. 18; no. 1; pp. 460 - 13
Main Authors Chen, Zhongli, Ding, Song, Wang, Yan Ping, Chen, Liang, Mao, Jing Yan, Yang, Ying, Sun, Jia Teng, Yang, Ke
Format Journal Article
LanguageEnglish
Published England BioMed Central Ltd 03.12.2020
BioMed Central
BMC
Subjects
Angiography
Antibodies
Arteriosclerosis
Atherogenesis
Carbamyl-lysine,coronary artery disease
Carbamylation
Cardiovascular disease
Cell activation
Cell adhesion & migration
Cell adhesion molecules
Cell surface
Cholesterol
Complications and side effects
Coronary artery
Coronary Artery Disease - complications
Coronary heart disease
Coronary vessels
Development and progression
Diabetes
Diabetes mellitus (non-insulin dependent)
Diabetes Mellitus, Type 2 - complications
Endothelial Cells
Health aspects
Heart diseases
High density lipoprotein
High density lipoproteins
Humans
Inflammation
Kidney diseases
Laboratories
Lipids
Lipoproteins
Lipoproteins, HDL
Lysine
Medical imaging
Monocyte adhesion
Monocytes
NF-κB protein
Oxidative stress
Physiological aspects
Proteins
Risk factors
Signal transduction
Type 2 diabetes
Type 2 diabetes mellitus
China
United States > US
Carbamylation
Monocyte adhesion
Carbamyl-lysine,coronary artery disease
Type 2 diabetes mellitus
High-density lipoprotein
Online AccessGet full text

Cover

Abstract Increasing evidence showed that carbamylated lipoprotein accelerated atherosclerosis. However, whether such modification of high-density lipoprotein (HDL) particles alters in type 2 diabetes mellitus (T2DM) patients and facilitates vascular complications remains unclear. We aimed to investigate the alteration of the carbamylation in HDL among T2DM patients and clarify its potential role in atherogenesis. A total of 148 consecutive T2DM patients undergoning angiography and 40 age- and gender-matched control subjects were included. HDL was isolated from plasma samples, and the concentration of HDL carbamyl-lysine (HDL-CBL) was measured. Furthermore, the HDL from subjects and in-vitro carbamylated HDL (C-HDL) was incubated with endothelial cells and monocyte to endothelial cell adhesion. Adhesion molecule expression and signaling pathway were detected. Compared with the control group, the HDL-CBL level was remarkably increased in T2DM patients (6.13 ± 1.94 vs 12.00 ± 4.06 (ng/mg), P < 0.001). Of note, HDL-CBL demonstrated a more significant increase in T2DM patients with coronary artery disease (CAD) (n = 102) than those without CAD (n = 46) (12.75 ± 3.82 vs. 10.35 ± 4.11(ng/mg), P = 0.001). Multivariate logistic regression analysis demonstrated that higher HDL-CBL level was independently associated with a higher prevalence of CAD in diabetic patients after adjusting for established cofounders (adjusted odds ratio 1.174, 95% confidence Interval 1.045-1.319, p = 0.017). HDL from diabetic patients with CAD enhanced greater monocyte adhesion than that from the non-CAD or the control group (P < 0.001). Such pro-atherogenic capacity of diabetic HDL positively correlated with HDL-CBL level. Furthermore, in-vitro incubation of carbamylated HDL (C-HDL) with endothelial promoted monocyte to endothelial cell adhesion, induced upregulation of cell adhesion molecules expression, and activated NF-κB/p65 signaling in endothelial cells. Inhibiting carbamylation of HDL or NF-κB activation attenuated the monocyte to endothelial cell adhesion and cell surface adhesion molecules expression. Our study identified elevated carbamylation modification of HDL from T2DM patients, especially in those with concomitant CAD. We also evidenced that C-HDL enhanced monocyte to endothelial cell adhesion, indicating a potential pro-atherogenic role of C-HDL in atherosclerosis among T2DM patients. Trial registration https://register.clinicaltrials.gov , NCT04390711 Registered on 14 May 2020; Retrospectively registered.
AbstractList Background Increasing evidence showed that carbamylated lipoprotein accelerated atherosclerosis. However, whether such modification of high-density lipoprotein (HDL) particles alters in type 2 diabetes mellitus (T2DM) patients and facilitates vascular complications remains unclear. We aimed to investigate the alteration of the carbamylation in HDL among T2DM patients and clarify its potential role in atherogenesis. Methods A total of 148 consecutive T2DM patients undergoning angiography and 40 age- and gender-matched control subjects were included. HDL was isolated from plasma samples, and the concentration of HDL carbamyl-lysine (HDL-CBL) was measured. Furthermore, the HDL from subjects and in-vitro carbamylated HDL (C-HDL) was incubated with endothelial cells and monocyte to endothelial cell adhesion. Adhesion molecule expression and signaling pathway were detected. Results Compared with the control group, the HDL-CBL level was remarkably increased in T2DM patients (6.13 [+ or -] 1.94 vs 12.00 [+ or -] 4.06 (ng/mg), P < 0.001). Of note, HDL-CBL demonstrated a more significant increase in T2DM patients with coronary artery disease (CAD) (n = 102) than those without CAD (n = 46) (12.75 [+ or -] 3.82 vs. 10.35 [+ or -] 4.11(ng/mg), P = 0.001). Multivariate logistic regression analysis demonstrated that higher HDL-CBL level was independently associated with a higher prevalence of CAD in diabetic patients after adjusting for established cofounders (adjusted odds ratio 1.174, 95% confidence Interval 1.045-1.319, p = 0.017). HDL from diabetic patients with CAD enhanced greater monocyte adhesion than that from the non-CAD or the control group (P < 0.001). Such pro-atherogenic capacity of diabetic HDL positively correlated with HDL-CBL level. Furthermore, in-vitro incubation of carbamylated HDL (C-HDL) with endothelial promoted monocyte to endothelial cell adhesion, induced upregulation of cell adhesion molecules expression, and activated NF-κB/p65 signaling in endothelial cells. Inhibiting carbamylation of HDL or NF-κB activation attenuated the monocyte to endothelial cell adhesion and cell surface adhesion molecules expression. Conclusions Our study identified elevated carbamylation modification of HDL from T2DM patients, especially in those with concomitant CAD. We also evidenced that C-HDL enhanced monocyte to endothelial cell adhesion, indicating a potential pro-atherogenic role of C-HDL in atherosclerosis among T2DM patients. Trial registration Keywords: Carbamylation, Carbamyl-lysine,coronary artery disease, High-density lipoprotein, Monocyte adhesion, Type 2 diabetes mellitus
Background Increasing evidence showed that carbamylated lipoprotein accelerated atherosclerosis. However, whether such modification of high-density lipoprotein (HDL) particles alters in type 2 diabetes mellitus (T2DM) patients and facilitates vascular complications remains unclear. We aimed to investigate the alteration of the carbamylation in HDL among T2DM patients and clarify its potential role in atherogenesis. Methods A total of 148 consecutive T2DM patients undergoning angiography and 40 age- and gender-matched control subjects were included. HDL was isolated from plasma samples, and the concentration of HDL carbamyl-lysine (HDL-CBL) was measured. Furthermore, the HDL from subjects and in-vitro carbamylated HDL (C-HDL) was incubated with endothelial cells and monocyte to endothelial cell adhesion. Adhesion molecule expression and signaling pathway were detected. Results Compared with the control group, the HDL-CBL level was remarkably increased in T2DM patients (6.13 ± 1.94 vs 12.00 ± 4.06 (ng/mg), P < 0.001). Of note, HDL-CBL demonstrated a more significant increase in T2DM patients with coronary artery disease (CAD) (n = 102) than those without CAD (n = 46) (12.75 ± 3.82 vs. 10.35 ± 4.11(ng/mg), P = 0.001). Multivariate logistic regression analysis demonstrated that higher HDL-CBL level was independently associated with a higher prevalence of CAD in diabetic patients after adjusting for established cofounders (adjusted odds ratio 1.174, 95% confidence Interval 1.045–1.319, p = 0.017). HDL from diabetic patients with CAD enhanced greater monocyte adhesion than that from the non-CAD or the control group (P < 0.001). Such pro-atherogenic capacity of diabetic HDL positively correlated with HDL-CBL level. Furthermore, in-vitro incubation of carbamylated HDL (C-HDL) with endothelial promoted monocyte to endothelial cell adhesion, induced upregulation of cell adhesion molecules expression, and activated NF-κB/p65 signaling in endothelial cells. Inhibiting carbamylation of HDL or NF-κB activation attenuated the monocyte to endothelial cell adhesion and cell surface adhesion molecules expression. Conclusions Our study identified elevated carbamylation modification of HDL from T2DM patients, especially in those with concomitant CAD. We also evidenced that C-HDL enhanced monocyte to endothelial cell adhesion, indicating a potential pro-atherogenic role of C-HDL in atherosclerosis among T2DM patients. Trial registration https://register.clinicaltrials.gov, NCT04390711 Registered on 14 May 2020; Retrospectively registered
Increasing evidence showed that carbamylated lipoprotein accelerated atherosclerosis. However, whether such modification of high-density lipoprotein (HDL) particles alters in type 2 diabetes mellitus (T2DM) patients and facilitates vascular complications remains unclear. We aimed to investigate the alteration of the carbamylation in HDL among T2DM patients and clarify its potential role in atherogenesis. A total of 148 consecutive T2DM patients undergoning angiography and 40 age- and gender-matched control subjects were included. HDL was isolated from plasma samples, and the concentration of HDL carbamyl-lysine (HDL-CBL) was measured. Furthermore, the HDL from subjects and in-vitro carbamylated HDL (C-HDL) was incubated with endothelial cells and monocyte to endothelial cell adhesion. Adhesion molecule expression and signaling pathway were detected. Compared with the control group, the HDL-CBL level was remarkably increased in T2DM patients (6.13 ± 1.94 vs 12.00 ± 4.06 (ng/mg), P < 0.001). Of note, HDL-CBL demonstrated a more significant increase in T2DM patients with coronary artery disease (CAD) (n = 102) than those without CAD (n = 46) (12.75 ± 3.82 vs. 10.35 ± 4.11(ng/mg), P = 0.001). Multivariate logistic regression analysis demonstrated that higher HDL-CBL level was independently associated with a higher prevalence of CAD in diabetic patients after adjusting for established cofounders (adjusted odds ratio 1.174, 95% confidence Interval 1.045-1.319, p = 0.017). HDL from diabetic patients with CAD enhanced greater monocyte adhesion than that from the non-CAD or the control group (P < 0.001). Such pro-atherogenic capacity of diabetic HDL positively correlated with HDL-CBL level. Furthermore, in-vitro incubation of carbamylated HDL (C-HDL) with endothelial promoted monocyte to endothelial cell adhesion, induced upregulation of cell adhesion molecules expression, and activated NF-κB/p65 signaling in endothelial cells. Inhibiting carbamylation of HDL or NF-κB activation attenuated the monocyte to endothelial cell adhesion and cell surface adhesion molecules expression. Our study identified elevated carbamylation modification of HDL from T2DM patients, especially in those with concomitant CAD. We also evidenced that C-HDL enhanced monocyte to endothelial cell adhesion, indicating a potential pro-atherogenic role of C-HDL in atherosclerosis among T2DM patients. Trial registration https://register.clinicaltrials.gov , NCT04390711 Registered on 14 May 2020; Retrospectively registered.
Increasing evidence showed that carbamylated lipoprotein accelerated atherosclerosis. However, whether such modification of high-density lipoprotein (HDL) particles alters in type 2 diabetes mellitus (T2DM) patients and facilitates vascular complications remains unclear. We aimed to investigate the alteration of the carbamylation in HDL among T2DM patients and clarify its potential role in atherogenesis. A total of 148 consecutive T2DM patients undergoning angiography and 40 age- and gender-matched control subjects were included. HDL was isolated from plasma samples, and the concentration of HDL carbamyl-lysine (HDL-CBL) was measured. Furthermore, the HDL from subjects and in-vitro carbamylated HDL (C-HDL) was incubated with endothelial cells and monocyte to endothelial cell adhesion. Adhesion molecule expression and signaling pathway were detected. Compared with the control group, the HDL-CBL level was remarkably increased in T2DM patients (6.13 [+ or -] 1.94 vs 12.00 [+ or -] 4.06 (ng/mg), P < 0.001). Of note, HDL-CBL demonstrated a more significant increase in T2DM patients with coronary artery disease (CAD) (n = 102) than those without CAD (n = 46) (12.75 [+ or -] 3.82 vs. 10.35 [+ or -] 4.11(ng/mg), P = 0.001). Multivariate logistic regression analysis demonstrated that higher HDL-CBL level was independently associated with a higher prevalence of CAD in diabetic patients after adjusting for established cofounders (adjusted odds ratio 1.174, 95% confidence Interval 1.045-1.319, p = 0.017). HDL from diabetic patients with CAD enhanced greater monocyte adhesion than that from the non-CAD or the control group (P < 0.001). Such pro-atherogenic capacity of diabetic HDL positively correlated with HDL-CBL level. Furthermore, in-vitro incubation of carbamylated HDL (C-HDL) with endothelial promoted monocyte to endothelial cell adhesion, induced upregulation of cell adhesion molecules expression, and activated NF-κB/p65 signaling in endothelial cells. Inhibiting carbamylation of HDL or NF-κB activation attenuated the monocyte to endothelial cell adhesion and cell surface adhesion molecules expression. Our study identified elevated carbamylation modification of HDL from T2DM patients, especially in those with concomitant CAD. We also evidenced that C-HDL enhanced monocyte to endothelial cell adhesion, indicating a potential pro-atherogenic role of C-HDL in atherosclerosis among T2DM patients.
Increasing evidence showed that carbamylated lipoprotein accelerated atherosclerosis. However, whether such modification of high-density lipoprotein (HDL) particles alters in type 2 diabetes mellitus (T2DM) patients and facilitates vascular complications remains unclear. We aimed to investigate the alteration of the carbamylation in HDL among T2DM patients and clarify its potential role in atherogenesis.BACKGROUNDIncreasing evidence showed that carbamylated lipoprotein accelerated atherosclerosis. However, whether such modification of high-density lipoprotein (HDL) particles alters in type 2 diabetes mellitus (T2DM) patients and facilitates vascular complications remains unclear. We aimed to investigate the alteration of the carbamylation in HDL among T2DM patients and clarify its potential role in atherogenesis.A total of 148 consecutive T2DM patients undergoning angiography and 40 age- and gender-matched control subjects were included. HDL was isolated from plasma samples, and the concentration of HDL carbamyl-lysine (HDL-CBL) was measured. Furthermore, the HDL from subjects and in-vitro carbamylated HDL (C-HDL) was incubated with endothelial cells and monocyte to endothelial cell adhesion. Adhesion molecule expression and signaling pathway were detected.METHODSA total of 148 consecutive T2DM patients undergoning angiography and 40 age- and gender-matched control subjects were included. HDL was isolated from plasma samples, and the concentration of HDL carbamyl-lysine (HDL-CBL) was measured. Furthermore, the HDL from subjects and in-vitro carbamylated HDL (C-HDL) was incubated with endothelial cells and monocyte to endothelial cell adhesion. Adhesion molecule expression and signaling pathway were detected.Compared with the control group, the HDL-CBL level was remarkably increased in T2DM patients (6.13 ± 1.94 vs 12.00 ± 4.06 (ng/mg), P < 0.001). Of note, HDL-CBL demonstrated a more significant increase in T2DM patients with coronary artery disease (CAD) (n = 102) than those without CAD (n = 46) (12.75 ± 3.82 vs. 10.35 ± 4.11(ng/mg), P = 0.001). Multivariate logistic regression analysis demonstrated that higher HDL-CBL level was independently associated with a higher prevalence of CAD in diabetic patients after adjusting for established cofounders (adjusted odds ratio 1.174, 95% confidence Interval 1.045-1.319, p = 0.017). HDL from diabetic patients with CAD enhanced greater monocyte adhesion than that from the non-CAD or the control group (P < 0.001). Such pro-atherogenic capacity of diabetic HDL positively correlated with HDL-CBL level. Furthermore, in-vitro incubation of carbamylated HDL (C-HDL) with endothelial promoted monocyte to endothelial cell adhesion, induced upregulation of cell adhesion molecules expression, and activated NF-κB/p65 signaling in endothelial cells. Inhibiting carbamylation of HDL or NF-κB activation attenuated the monocyte to endothelial cell adhesion and cell surface adhesion molecules expression.RESULTSCompared with the control group, the HDL-CBL level was remarkably increased in T2DM patients (6.13 ± 1.94 vs 12.00 ± 4.06 (ng/mg), P < 0.001). Of note, HDL-CBL demonstrated a more significant increase in T2DM patients with coronary artery disease (CAD) (n = 102) than those without CAD (n = 46) (12.75 ± 3.82 vs. 10.35 ± 4.11(ng/mg), P = 0.001). Multivariate logistic regression analysis demonstrated that higher HDL-CBL level was independently associated with a higher prevalence of CAD in diabetic patients after adjusting for established cofounders (adjusted odds ratio 1.174, 95% confidence Interval 1.045-1.319, p = 0.017). HDL from diabetic patients with CAD enhanced greater monocyte adhesion than that from the non-CAD or the control group (P < 0.001). Such pro-atherogenic capacity of diabetic HDL positively correlated with HDL-CBL level. Furthermore, in-vitro incubation of carbamylated HDL (C-HDL) with endothelial promoted monocyte to endothelial cell adhesion, induced upregulation of cell adhesion molecules expression, and activated NF-κB/p65 signaling in endothelial cells. Inhibiting carbamylation of HDL or NF-κB activation attenuated the monocyte to endothelial cell adhesion and cell surface adhesion molecules expression.Our study identified elevated carbamylation modification of HDL from T2DM patients, especially in those with concomitant CAD. We also evidenced that C-HDL enhanced monocyte to endothelial cell adhesion, indicating a potential pro-atherogenic role of C-HDL in atherosclerosis among T2DM patients. Trial registration https://register.clinicaltrials.gov , NCT04390711 Registered on 14 May 2020; Retrospectively registered.CONCLUSIONSOur study identified elevated carbamylation modification of HDL from T2DM patients, especially in those with concomitant CAD. We also evidenced that C-HDL enhanced monocyte to endothelial cell adhesion, indicating a potential pro-atherogenic role of C-HDL in atherosclerosis among T2DM patients. Trial registration https://register.clinicaltrials.gov , NCT04390711 Registered on 14 May 2020; Retrospectively registered.
Abstract Background Increasing evidence showed that carbamylated lipoprotein accelerated atherosclerosis. However, whether such modification of high-density lipoprotein (HDL) particles alters in type 2 diabetes mellitus (T2DM) patients and facilitates vascular complications remains unclear. We aimed to investigate the alteration of the carbamylation in HDL among T2DM patients and clarify its potential role in atherogenesis. Methods A total of 148 consecutive T2DM patients undergoning angiography and 40 age- and gender-matched control subjects were included. HDL was isolated from plasma samples, and the concentration of HDL carbamyl-lysine (HDL-CBL) was measured. Furthermore, the HDL from subjects and in-vitro carbamylated HDL (C-HDL) was incubated with endothelial cells and monocyte to endothelial cell adhesion. Adhesion molecule expression and signaling pathway were detected. Results Compared with the control group, the HDL-CBL level was remarkably increased in T2DM patients (6.13 ± 1.94 vs 12.00 ± 4.06 (ng/mg), P < 0.001). Of note, HDL-CBL demonstrated a more significant increase in T2DM patients with coronary artery disease (CAD) (n = 102) than those without CAD (n = 46) (12.75 ± 3.82 vs. 10.35 ± 4.11(ng/mg), P = 0.001). Multivariate logistic regression analysis demonstrated that higher HDL-CBL level was independently associated with a higher prevalence of CAD in diabetic patients after adjusting for established cofounders (adjusted odds ratio 1.174, 95% confidence Interval 1.045–1.319, p = 0.017). HDL from diabetic patients with CAD enhanced greater monocyte adhesion than that from the non-CAD or the control group (P < 0.001). Such pro-atherogenic capacity of diabetic HDL positively correlated with HDL-CBL level. Furthermore, in-vitro incubation of carbamylated HDL (C-HDL) with endothelial promoted monocyte to endothelial cell adhesion, induced upregulation of cell adhesion molecules expression, and activated NF-κB/p65 signaling in endothelial cells. Inhibiting carbamylation of HDL or NF-κB activation attenuated the monocyte to endothelial cell adhesion and cell surface adhesion molecules expression. Conclusions Our study identified elevated carbamylation modification of HDL from T2DM patients, especially in those with concomitant CAD. We also evidenced that C-HDL enhanced monocyte to endothelial cell adhesion, indicating a potential pro-atherogenic role of C-HDL in atherosclerosis among T2DM patients. Trial registration https://register.clinicaltrials.gov , NCT04390711 Registered on 14 May 2020; Retrospectively registered
ArticleNumber 460
Audience Academic
Author Ding, Song
Chen, Liang
Chen, Zhongli
Yang, Ying
Yang, Ke
Mao, Jing Yan
Sun, Jia Teng
Wang, Yan Ping
Author_xml – sequence: 1
  givenname: Zhongli
  surname: Chen
  fullname: Chen, Zhongli
– sequence: 2
  givenname: Song
  surname: Ding
  fullname: Ding, Song
– sequence: 3
  givenname: Yan Ping
  surname: Wang
  fullname: Wang, Yan Ping
– sequence: 4
  givenname: Liang
  surname: Chen
  fullname: Chen, Liang
– sequence: 5
  givenname: Jing Yan
  surname: Mao
  fullname: Mao, Jing Yan
– sequence: 6
  givenname: Ying
  surname: Yang
  fullname: Yang, Ying
– sequence: 7
  givenname: Jia Teng
  surname: Sun
  fullname: Sun, Jia Teng
– sequence: 8
  givenname: Ke
  orcidid: 0000-0003-3135-2669
  surname: Yang
  fullname: Yang, Ke
BackLink https://www.ncbi.nlm.nih.gov/pubmed/33272295$$D View this record in MEDLINE/PubMed
BookMark eNqNkl1rFDEUhgep2A_9A15IwBtvpk6SSTLxQliKH4WCN3odMvnYTZlJ1iRb2d_mn_N0t9VuEZFhyHDynmfOe3hPm6OYomual7g7x3jgbwsmkou2Ix28nNCWPGlOcC9kywbBjx58HzenpVx3HelZL581x5QSQYhkJ83PRSnJBF1Diih5ZHQe9byddHUWrcJy1VoXS6hbNIV1WudUXYjoR6grZFJOUect0rk6OGwoTheH4L5u1w4RqOjRVVfQ7KYp1E159598GGQNI7lYC4LanHaQFJPZVoe0XbkC8z5vnno9Fffi7jxrvn388PXic3v15dPlxeKqNYzT2vZc9sRybC31WGtix1EwN0hiLJacOIOtFEbIUfKRs8EPgg6E-l54JnuKPT1rLvdcm_S1Wucwg2uVdFC7QspLBSsIZnJKmIFZ6wWzgvZMmsFIRrA3hIkRa4qB9X7PWm_G2VkDFrOeDqCHNzGs1DLdKCEwxbwHwJs7QE7fN65UNYdiYL86urQpivRccMwF6UD6-pH0Om1yhFWBSmAwL_nwR7XUYCBEn-C_5haqFpx1nEhBKKjO_6KCx7o5GMilD1A_aHj10Ohvh_fRA8GwF5icSsnOKxPqLodADpPCnbpNudqnXEHK1S7likAredR6T_9H0y8HpAMn
CitedBy_id crossref_primary_10_1016_j_jbc_2022_101832
crossref_primary_10_1007_s10787_021_00887_8
crossref_primary_10_1007_s11906_022_01203_7
crossref_primary_10_1155_2023_4574042
crossref_primary_10_3390_metabo13020253
crossref_primary_10_3389_fcell_2021_674103
crossref_primary_10_3390_antiox13010057
crossref_primary_10_1016_j_pcad_2024_10_009
crossref_primary_10_4239_wjd_v14_i3_159
crossref_primary_10_3390_cells13131113
crossref_primary_10_1186_s12933_022_01591_9
crossref_primary_10_3389_fcvm_2022_841545
Cites_doi 10.1016/j.amjcard.2016.08.044
10.1373/clinchem.2011.163188
10.1681/ASN.2012030254
10.1038/nrcardio.2015.124
10.1006/bbrc.2001.6067
10.1016/j.jacc.2016.07.755
10.1186/s12944-017-0594-3
10.2215/CJN.11710919
10.1186/s12933-017-0613-8
10.1074/jbc.M009705200
10.1161/ATVBAHA.118.307026
10.2174/092986707779941032
10.1016/j.biochi.2018.04.018
10.1038/nrneph.2017.103
10.1016/j.kint.2018.01.033
10.1161/CIRCRESAHA.116.306923
10.1681/ASN.2014101047
10.1038/nm1637
10.1152/ajprenal.00508.2015
10.1172/JCI200421109
10.3760/cma.j.issn.0366-6999.20131149
10.1210/jc.2017-01551
10.1089/ars.2010.3640
10.1161/01.RES.85.2.199
10.1093/ndt/gfv048
10.1016/j.jacc.2016.08.006
10.1007/s12265-019-09903-3
10.1016/j.metabol.2014.10.020
10.1089/ars.2011.4403
10.1038/ki.2015.166
10.2337/dc18-S002
10.1016/S0891-5849(00)00229-X
10.1126/scitranslmed.3005218
10.1007/s11892-017-0891-2
10.1042/CS20130369
10.1016/bs.acc.2018.07.002
10.1016/S2213-8587(19)30003-8
10.1074/jbc.M109.047605
10.1056/NEJMoa1001689
10.4049/jimmunol.1300155
ContentType Journal Article
Copyright COPYRIGHT 2020 BioMed Central Ltd.
2020. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
The Author(s) 2020
Copyright_xml – notice: COPYRIGHT 2020 BioMed Central Ltd.
– notice: 2020. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: The Author(s) 2020
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7T5
7X7
7XB
88E
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
H94
K9.
M0S
M1P
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
DOA
DOI 10.1186/s12967-020-02623-2
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Immunology Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials Local Electronic Collection Information
ProQuest Central
ProQuest One
ProQuest Central
Health Research Premium Collection
Health Research Premium Collection (Alumni)
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Health & Medical Collection (Alumni)
Proquest Medical Database
ProQuest Central Premium
ProQuest One Academic
ProQuest Publicly Available Content
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Central China
ProQuest Central
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Health & Medical Research Collection
AIDS and Cancer Research Abstracts
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
Immunology Abstracts
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList
Publicly Available Content Database
MEDLINE

MEDLINE - Academic
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 4
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1479-5876
EndPage 13
ExternalDocumentID oai_doaj_org_article_7c85ddf75d73459c8c9521fc257b1a31
PMC7713164
A650629723
33272295
10_1186_s12967_020_02623_2
Genre Research Support, Non-U.S. Gov't
Journal Article
Observational Study
GeographicLocations China
United States--US
GeographicLocations_xml – name: China
– name: United States--US
GrantInformation_xml – fundername: the Natural Science Foundation of Yunnan Province
  grantid: 2017FA048
– fundername: National Natural Science Foundation of China
  grantid: 31660313
– fundername: Shanghai Sailing Program
  grantid: 18YF1413500
– fundername: National Natural Science Foundation of China
  grantid: 81760734
– fundername: National Natural Science Foundation of China
  grantid: 81770384
– fundername: National Natural Science Foundation of China
  grantid: 81800223
– fundername: Shanghai Science and Technology Committee
  grantid: 19ZR1430400
– fundername: ;
  grantid: 19ZR1430400
– fundername: ;
  grantid: 18YF1413500
– fundername: ;
  grantid: 2017FA048
– fundername: ;
  grantid: 81800223; 81760734; 31660313
– fundername: ;
  grantid: 81770384
GroupedDBID ---
0R~
29L
2WC
53G
5VS
6PF
7X7
88E
8FI
8FJ
AAFWJ
AAJSJ
AASML
AAWTL
AAYXX
ABDBF
ABUWG
ACGFO
ACGFS
ACIHN
ACIWK
ACPRK
ACUHS
ADBBV
ADUKV
AEAQA
AENEX
AFKRA
AFPKN
AFRAH
AHBYD
AHMBA
AHYZX
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AOIJS
BAPOH
BAWUL
BCNDV
BENPR
BFQNJ
BMC
BPHCQ
BVXVI
C6C
CCPQU
CITATION
CS3
DIK
DU5
E3Z
EBD
EBLON
EBS
ESX
F5P
FYUFA
GROUPED_DOAJ
GX1
HMCUK
HYE
IAO
IHR
INH
INR
ITC
KQ8
M1P
M48
M~E
O5R
O5S
OK1
OVT
P2P
PGMZT
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
PSQYO
RBZ
RNS
ROL
RPM
RSV
SBL
SOJ
TR2
TUS
UKHRP
WOQ
WOW
XSB
~8M
CGR
CUY
CVF
ECM
EIF
NPM
PJZUB
PPXIY
PMFND
3V.
7T5
7XB
8FK
AZQEC
DWQXO
H94
K9.
PKEHL
PQEST
PQUKI
PRINS
7X8
PUEGO
5PM
ID FETCH-LOGICAL-c563t-46942d61dd3f1aa2dbb75e892cd1962ec1d97c79b96b658f873823f47f59431f3
IEDL.DBID 7X7
ISSN 1479-5876
IngestDate Wed Aug 27 01:19:58 EDT 2025
Thu Aug 21 18:13:50 EDT 2025
Sun Aug 24 04:00:02 EDT 2025
Fri Jul 25 02:55:11 EDT 2025
Tue Jun 17 21:25:35 EDT 2025
Tue Jun 10 20:27:31 EDT 2025
Tue Jul 29 01:37:21 EDT 2025
Tue Jul 01 03:51:15 EDT 2025
Thu Apr 24 22:59:47 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Carbamylation
Monocyte adhesion
Carbamyl-lysine,coronary artery disease
Type 2 diabetes mellitus
High-density lipoprotein
Language English
License Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c563t-46942d61dd3f1aa2dbb75e892cd1962ec1d97c79b96b658f873823f47f59431f3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0003-3135-2669
OpenAccessLink https://www.proquest.com/docview/2471196968?pq-origsite=%requestingapplication%
PMID 33272295
PQID 2471196968
PQPubID 43076
PageCount 13
ParticipantIDs doaj_primary_oai_doaj_org_article_7c85ddf75d73459c8c9521fc257b1a31
pubmedcentral_primary_oai_pubmedcentral_nih_gov_7713164
proquest_miscellaneous_2467616720
proquest_journals_2471196968
gale_infotracmisc_A650629723
gale_infotracacademiconefile_A650629723
pubmed_primary_33272295
crossref_citationtrail_10_1186_s12967_020_02623_2
crossref_primary_10_1186_s12967_020_02623_2
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2020-12-03
PublicationDateYYYYMMDD 2020-12-03
PublicationDate_xml – month: 12
  year: 2020
  text: 2020-12-03
  day: 03
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
– name: London
PublicationTitle Journal of translational medicine
PublicationTitleAlternate J Transl Med
PublicationYear 2020
Publisher BioMed Central Ltd
BioMed Central
BMC
Publisher_xml – name: BioMed Central Ltd
– name: BioMed Central
– name: BMC
References JT Sun (2623_CR20) 2016; 310
J Long (2623_CR14) 2018; 87
EA Podrez (2623_CR32) 2000; 28
JT Sun (2623_CR13) 2016; 5
RA Koeth (2623_CR15) 2013; 24
WH Tang (2623_CR18) 2016; 68
RFH Lemmers (2623_CR41) 2017; 11
PR Gajjala (2623_CR10) 2015; 30
EW Holy (2623_CR22) 2016; 68
JT Sun (2623_CR4) 2016; 118
K Iiyama (2623_CR28) 1999; 85
JT Sun (2623_CR36) 2013; 126
FH Verbrugge (2623_CR17) 2015; 88
M Holzer (2623_CR33) 2012; 17
KCB Tan (2623_CR34) 2020; 15
Classification and diagnosis of diabetes (2623_CR21) 2018; 41
AS Xiang (2623_CR1) 2019; 7
M Femlak (2623_CR5) 2017; 16
R Kaseda (2623_CR39) 2015; 64
L Zheng (2623_CR8) 2004; 114
S Nakajima (2623_CR25) 2013; 190
Y Chen (2623_CR9) 2018; 153
Z Wang (2623_CR16) 2007; 13
SR Kashyap (2623_CR35) 2018; 103
M Holzer (2623_CR19) 2011; 14
I Kim (2623_CR29) 2001; 276
S Zewinger (2623_CR40) 2015; 36
AH Berg (2623_CR24) 2013; 5
YF Xia (2623_CR27) 2001; 289
C Luévano-Contreras (2623_CR37) 2017; 17
BA Di Bartolo (2623_CR2) 2018; 38
JT Sun (2623_CR7) 2019; 12
S Jaisson (2623_CR12) 2011; 57
H Kobayashi (2623_CR26) 2007; 14
A Undurti (2623_CR42) 2009; 284
D Mori (2623_CR23) 2018; 94
RS Rosenson (2623_CR3) 2016; 13
SW Shiu (2623_CR31) 2014; 126
AV Khera (2623_CR43) 2011; 364
S Delanghe (2623_CR11) 2017; 13
S Ebtehaj (2623_CR6) 2017; 16
MS Shah (2623_CR30) 2016; 118
AE Stinghen (2623_CR38) 2016; 27
References_xml – volume: 11
  start-page: e715
  issue: 712–724
  year: 2017
  ident: 2623_CR41
  publication-title: J Clin Lipidol
– volume: 118
  start-page: 1674
  year: 2016
  ident: 2623_CR4
  publication-title: Am J Cardiol
  doi: 10.1016/j.amjcard.2016.08.044
– volume: 57
  start-page: 1499
  year: 2011
  ident: 2623_CR12
  publication-title: Clin Chem
  doi: 10.1373/clinchem.2011.163188
– volume: 24
  start-page: 853
  year: 2013
  ident: 2623_CR15
  publication-title: J Am Soc Nephrol
  doi: 10.1681/ASN.2012030254
– volume: 13
  start-page: 48
  year: 2016
  ident: 2623_CR3
  publication-title: Nat Rev Cardiol
  doi: 10.1038/nrcardio.2015.124
– volume: 289
  start-page: 851
  year: 2001
  ident: 2623_CR27
  publication-title: Biochem Biophys Res Commun
  doi: 10.1006/bbrc.2001.6067
– volume: 36
  start-page: 3007
  year: 2015
  ident: 2623_CR40
  publication-title: Eur Heart J
– volume: 68
  start-page: 1664
  year: 2016
  ident: 2623_CR22
  publication-title: J Am Coll Cardiol
  doi: 10.1016/j.jacc.2016.07.755
– volume: 16
  start-page: 207
  year: 2017
  ident: 2623_CR5
  publication-title: Lipids Health Dis
  doi: 10.1186/s12944-017-0594-3
– volume: 15
  start-page: 359
  year: 2020
  ident: 2623_CR34
  publication-title: Clin J Am Soc Nephrol
  doi: 10.2215/CJN.11710919
– volume: 16
  start-page: 132
  year: 2017
  ident: 2623_CR6
  publication-title: Cardiovascular diabetology
  doi: 10.1186/s12933-017-0613-8
– volume: 276
  start-page: 7614
  year: 2001
  ident: 2623_CR29
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M009705200
– volume: 38
  start-page: 1961
  year: 2018
  ident: 2623_CR2
  publication-title: Arterioscler Thromb Vasc Biol
  doi: 10.1161/ATVBAHA.118.307026
– volume: 14
  start-page: 377
  year: 2007
  ident: 2623_CR26
  publication-title: Curr Med Chem
  doi: 10.2174/092986707779941032
– volume: 153
  start-page: 232
  year: 2018
  ident: 2623_CR9
  publication-title: Biochimie
  doi: 10.1016/j.biochi.2018.04.018
– volume: 13
  start-page: 580
  year: 2017
  ident: 2623_CR11
  publication-title: Nat Rev Nephrol
  doi: 10.1038/nrneph.2017.103
– volume: 94
  start-page: 72
  year: 2018
  ident: 2623_CR23
  publication-title: Kidney Int
  doi: 10.1016/j.kint.2018.01.033
– volume: 118
  start-page: 1808
  year: 2016
  ident: 2623_CR30
  publication-title: Circ Res
  doi: 10.1161/CIRCRESAHA.116.306923
– volume: 27
  start-page: 354
  year: 2016
  ident: 2623_CR38
  publication-title: J Am Soc Nephrol
  doi: 10.1681/ASN.2014101047
– volume: 5
  start-page: 1
  year: 2016
  ident: 2623_CR13
  publication-title: J Am Heart Assoc.
– volume: 13
  start-page: 1176
  year: 2007
  ident: 2623_CR16
  publication-title: Nat Med
  doi: 10.1038/nm1637
– volume: 310
  start-page: F511
  year: 2016
  ident: 2623_CR20
  publication-title: Am J Physiol Renal Physiol
  doi: 10.1152/ajprenal.00508.2015
– volume: 114
  start-page: 529
  year: 2004
  ident: 2623_CR8
  publication-title: J Clin Investig
  doi: 10.1172/JCI200421109
– volume: 126
  start-page: 4162
  year: 2013
  ident: 2623_CR36
  publication-title: Chin Med J
  doi: 10.3760/cma.j.issn.0366-6999.20131149
– volume: 103
  start-page: 388
  year: 2018
  ident: 2623_CR35
  publication-title: J Clin Endocrinol Metab
  doi: 10.1210/jc.2017-01551
– volume: 14
  start-page: 2337
  year: 2011
  ident: 2623_CR19
  publication-title: Antioxid Redox Signal
  doi: 10.1089/ars.2010.3640
– volume: 85
  start-page: 199
  year: 1999
  ident: 2623_CR28
  publication-title: Circ Res
  doi: 10.1161/01.RES.85.2.199
– volume: 30
  start-page: 1814
  year: 2015
  ident: 2623_CR10
  publication-title: Nephrol Dialys Transpl
  doi: 10.1093/ndt/gfv048
– volume: 68
  start-page: 1677
  year: 2016
  ident: 2623_CR18
  publication-title: J Am Coll Cardiol
  doi: 10.1016/j.jacc.2016.08.006
– volume: 12
  start-page: 560
  year: 2019
  ident: 2623_CR7
  publication-title: J Cardiovasc Transl Res
  doi: 10.1007/s12265-019-09903-3
– volume: 64
  start-page: 263
  year: 2015
  ident: 2623_CR39
  publication-title: Metabolism.
  doi: 10.1016/j.metabol.2014.10.020
– volume: 17
  start-page: 1043
  year: 2012
  ident: 2623_CR33
  publication-title: Antioxid Redox Signal
  doi: 10.1089/ars.2011.4403
– volume: 88
  start-page: 474
  year: 2015
  ident: 2623_CR17
  publication-title: Kidney Int
  doi: 10.1038/ki.2015.166
– volume: 41
  start-page: S13
  year: 2018
  ident: 2623_CR21
  publication-title: Diabetes Care
  doi: 10.2337/dc18-S002
– volume: 28
  start-page: 1717
  year: 2000
  ident: 2623_CR32
  publication-title: Free Radical Biol Med
  doi: 10.1016/S0891-5849(00)00229-X
– volume: 5
  start-page: 175ra129
  year: 2013
  ident: 2623_CR24
  publication-title: Sci Transl Med.
  doi: 10.1126/scitranslmed.3005218
– volume: 17
  start-page: 63
  year: 2017
  ident: 2623_CR37
  publication-title: Curr DiabRep
  doi: 10.1007/s11892-017-0891-2
– volume: 126
  start-page: 175
  year: 2014
  ident: 2623_CR31
  publication-title: Clin Sci.
  doi: 10.1042/CS20130369
– volume: 87
  start-page: 37
  year: 2018
  ident: 2623_CR14
  publication-title: Adv Clin Chem
  doi: 10.1016/bs.acc.2018.07.002
– volume: 7
  start-page: 575
  year: 2019
  ident: 2623_CR1
  publication-title: Lancet Diabetes Endocrinol
  doi: 10.1016/S2213-8587(19)30003-8
– volume: 284
  start-page: 30825
  year: 2009
  ident: 2623_CR42
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M109.047605
– volume: 364
  start-page: 127
  year: 2011
  ident: 2623_CR43
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1001689
– volume: 190
  start-page: 6559
  year: 2013
  ident: 2623_CR25
  publication-title: J Immunol.
  doi: 10.4049/jimmunol.1300155
SSID ssj0024549
Score 2.3634877
Snippet Increasing evidence showed that carbamylated lipoprotein accelerated atherosclerosis. However, whether such modification of high-density lipoprotein (HDL)...
Background Increasing evidence showed that carbamylated lipoprotein accelerated atherosclerosis. However, whether such modification of high-density lipoprotein...
Abstract Background Increasing evidence showed that carbamylated lipoprotein accelerated atherosclerosis. However, whether such modification of high-density...
SourceID doaj
pubmedcentral
proquest
gale
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 460
SubjectTerms Angiography
Antibodies
Arteriosclerosis
Atherogenesis
Carbamyl-lysine,coronary artery disease
Carbamylation
Cardiovascular disease
Cell activation
Cell adhesion & migration
Cell adhesion molecules
Cell surface
Cholesterol
Complications and side effects
Coronary artery
Coronary Artery Disease - complications
Coronary heart disease
Coronary vessels
Development and progression
Diabetes
Diabetes mellitus (non-insulin dependent)
Diabetes Mellitus, Type 2 - complications
Endothelial Cells
Health aspects
Heart diseases
High density lipoprotein
High density lipoproteins
Humans
Inflammation
Kidney diseases
Laboratories
Lipids
Lipoproteins
Lipoproteins, HDL
Lysine
Medical imaging
Monocyte adhesion
Monocytes
NF-κB protein
Oxidative stress
Physiological aspects
Proteins
Risk factors
Signal transduction
Type 2 diabetes
Type 2 diabetes mellitus
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1La9wwEBYlh9JLafp0mxYVCj0Uk_XYkuzc0tIQCumpgdyEnmRhYy9Z72F_W_9cZ2R7WVNoe-jVGhlJM9I8NPqGsQ-FjItIcY0QQZGD4nOjGpFLHz1UFkSU9MD56ru8vK6-3Yibg1JflBM2wAMPC3eqXC28j0p4VVaicbVrUONEh6JmC5NeUAPqvMmZmlD20O2ZnsjU8nSDWg0PBHKV0OeAMoeZGkpo_b-fyQdKaZ4weaCBLp6wx6PpyM-HIR-zB6F9yh5ejZfjz9jPg6XmXeSOrhLudiu0Jj0nWOLcU7Z6v-Or5bpLAA3LllMgljvCMTD3O54yPHd8vLbh2E4xWg58itHyO0Lw7Lebs3_8Pw5kxG7d8HXK_aOfdG3ndn3gxt8Gitc9Z9cXX398uczH2gy5E7Lsc_SqK_Cy8L6MhTHgrVUi1A04j3sagit8o5xqbCMtGjmxVnThGCsVRYM2SyxfsKO2a8MrxsEgI6VZ2OhjJYM1BHEmYu2s8oDkGSsmVmk3ApdT_YyVTg5MLfXAXo3s1Ym9GjL2ad9nPcB2_JH6M0nAnpIgt9MHFEQ9CqL-myBm7CPJj6aDAYfnzPi-ASdJEFv6HG1hCVTkLWMnM0rc0G7ePEmgHg-UjQY0IgYko4y93zdTT0qSa0O3JRqpZCEVLDL2chDY_ZTKEhRVbs-YmonybM7zlnZ5m-DGlSpKZMnr_7FIb9gjoF1I-UDlCTvq77fhLVp1vX2XNvAvXCxN9g
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Scholars Portal Journals: Open Access
  dbid: M48
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3di9QwEA_HCeKL-G29UyIIPkh1mzRJK4ic4nEI65ML9xbSfHgLe-3ebheuf5v_nDPZdt3icfi6mZRkZybzkclvCHmTyTAJmNfwgSkMUFxqVClS6YJjecVEkPjAefpDns3y7-fi_IAM7Y76P3B9Y2iH_aRmq8X766vuMyj8p6jwhfywBpsF6o6BEEQUjKdwJN8By6RQUad58Rd7D4Kh4eHMjfNGxili-P97Uu-ZqnEZ5Z5dOn1A7vcOJT3ZSsBDcuDrR-TutL8yf0x-7zGANoFavGC47BbgYzqKYMWpwxr2tqOL-bKJsA3zmmJ6llpENzCrjsa6z472lzkUxjFzSxkdMrf0EnE92836439-HxbSI7qu6TJWBOJHmrqxXeupcRces3hPyOz028-vZ2nfsSG1QvI2hVg7Z05mzvGQGcNcVSnhi5JZB5rOvM1cqawqq1JW4PqEQuE1ZMhVECV4MoE_JYd1U_vnhDJTZUaaSRVcyKWvDAKfiVDYSjkG5AnJBlZp28OZY1eNhY5hTSH1lr0a2KsjezVLyLvdnOUWzONW6i8oATtKBOKOPzSrX7rXa61sIZwLSjjFc1HawpbgEAULJyGsn2cJeYvyo1GAYXnW9K8eYJMIvKVPwEOWDFu_JeR4RAlqbsfDgwTqQUs0A9dii2-UkNe7YZyJpXO1bzZII5XMpGKThDzbCuxuS5wzhf3cE6JGojza83iknl9EEHKlMg4seXH7so7IPYb6hfU__JgctquNfwleXFu9iqr5B_4xSNY
  priority: 102
  providerName: Scholars Portal
Title Association of carbamylated high-density lipoprotein with coronary artery disease in type 2 diabetes mellitus: carbamylated high-density lipoprotein of patients promotes monocyte adhesion
URI https://www.ncbi.nlm.nih.gov/pubmed/33272295
https://www.proquest.com/docview/2471196968
https://www.proquest.com/docview/2467616720
https://pubmed.ncbi.nlm.nih.gov/PMC7713164
https://doaj.org/article/7c85ddf75d73459c8c9521fc257b1a31
Volume 18
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3da9swEBdbC2MvY9_z1gUNBnsYprFsS_ZeRjNayiBllBXCXoStjzaQ2lnsPPhv2z-3O1lOYwZlL36IzkbKfejudPodIR8jbqcW8xrGMoEBig4Lkach11azpGSp5XjBeX7Bz6-S74t04RNujS-rHGyiM9S6VpgjP2ZgRXsol6_r3yF2jcLTVd9C4yE5ROgyLOkSi7uAK4HgZ7gok_HjBvY2MAsYMEHkweKQjTYjh9n_r2Xe25rGZZN7-9DZU_LEO5D0pOf4M_LAVM_Jo7k_In9B_uz94bS2VOGBwm23Ap9SUwQnDjXWrLcdXS3XtYNpWFYU07FUIZpBsemoq_PsqD-8oTCOmVrK6JCppbeI49lumy__-X2YiEdwbejaVQDiR-qqVl1raKFvDGbtXpKrs9Of385D36EhVCmP2xBi64RpHmkd26gomC5LkZosZ0oDr5hRkc6FEnmZ8xJcHZsJPHa0ibBpDp6LjV-Rg6quzBtCWVFGBS-mpdU24aYsEOgstZkqhWZAHpBoYJVUHr4cu2ispAtjMi579kpgr3TslSwgn3fvrHvwjnupZygBO0oE3nY_1Jtr6fVYCpWlWluRahEnaa4ylYMDZBVYPph_HAXkE8qPRPMA01OFv-UAi0SgLXkCHjFn2OotIEcjSlBrNR4eJFB6s9LIOyUIyIfdML6JpXKVqbdIwwWPuGDTgLzuBXa3pDhmAvu3B0SMRHm05vFItbxxoONCRDGw5O3903pHHjPUL6z3iY_IQbvZmvfgtbXlxKnmhBzOTi9-XE5c7gOe8ySD5-Xs119MWUo1
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1ba9RAFD7ULagv4t1o1REUHyR0M0lmEkGk1Zat7S4iLfRtTGYydmGbrN0skj_lH_DPeU4u2w1C8aWvmckwwzlz7vMdgNeesENLcY3MckkOinETGYeuMNbwIOWhFfTAeTwRo5Pgy2l4ugG_u7cwVFbZycRaUJtCU4x8m6MUbaBcPs5_utQ1irKrXQuNhi0Os-oXumyLDwefkb5vON_fO_40ctuuAq4OhV-66A8G3AjPGN96ScJNmsowi2KuDa7PM-2ZWGoZp7FIUT3bSFKqzAbShjFqW-vjujdgM_DRlRnA5u7e5Ou3S3Q_dLe6pzmR2F6gNkVBRC4a-jrcd3lP_dVdAv7VBWvKsF-ouab59u_CndZkZTsNj92DjSy_DzfHbVL-AfxZIzErLNOUwjivZmjFGkZwyK6hKvmyYrPpvKiBIaY5owAw04SfkFxUrK4srVibLmI4TrFhxlkXG2bnhBxaLhfv_3N93EiLGbtg87rmkBYp8kJXZcYSc5ZRnPAhnFwL9R7BIC_y7AkwnqReIpJhao0NRJYmBK0W2kin0nCc7oDXkUrpFjCd-nbMVO04RUI15FVIXlWTV3EH3q3-mTdwIVfO3iUOWM0kqO_6Q3HxQ7WSQ0kdhcZYGRrpB2GsIx2jyWU1ylrcv-858Jb4R5FAwu3ppH1XgYckaC-1gza44NRczoGt3kwUJLo_3HGgagXZQl1eOwderYbpTyrOy7NiSXOEFJ6QfOjA44ZhV0fyfS6pY7wDssfKvTP3R_LpWQ1zLqXnI0meXr2tl3BrdDw-UkcHk8NncJvTXaNqI38LBuXFMnuONmOZvmgvKoPv1y0b_gKWB4NW
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Association+of+carbamylated+high-density+lipoprotein+with+coronary+artery+disease+in+type+2+diabetes+mellitus%3A+carbamylated+high-density+lipoprotein+of+patients+promotes+monocyte+adhesion&rft.jtitle=Journal+of+translational+medicine&rft.au=Chen%2C+Zhongli&rft.au=Ding%2C+Song&rft.au=Wang%2C+Yan+Ping&rft.au=Chen%2C+Liang&rft.date=2020-12-03&rft.pub=BioMed+Central&rft.eissn=1479-5876&rft.volume=18&rft.spage=1&rft_id=info:doi/10.1186%2Fs12967-020-02623-2
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1479-5876&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1479-5876&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1479-5876&client=summon